PCN65 Cost-Effectiveness of Treating Metastatic Renal Cell Carcinoma (mRCC) Patients Whose Disease Failed on one Prior VEGF-TKI Therapy with Everolimus Compared to Treating with Best Supportive Care (BSC) Alone in Canada  by Casciano, R. et al.
sociated with treatment and productivity loss over a one year period at vaccine
steady state (i.e. when all women are vaccinated), current vs. future burden assum-
ing 95% vaccine coverage. The MR incidence data on abnormal PAP and CINs were
extrapolated from the relative proportion of abnormal PAP, precancerous lesions
and CC previously published. Vaccination effectiveness was based on clinical trial
data and HPV distribution for Russia and Eastern Europe. Medical costs were esti-
mated from resources used and listed Russian price. Indirect costs include unpaid
taxes, illness allowance and regional GDP foregone. No discount was applied. Sen-
sitivity analyses were conducted on main parameters (number of lesions, vaccine
effectiveness, costs). RESULTS: Vaccination with the bivalent HPV vaccine in the
MR was estimated to prevent 13,737 abnormal PAP (112.6 m.rub.), 11,750 CIN1 (296.1
m.rub.), 4,222 CIN2/3 (259.3 m.rub.), 504 CC (98.9 m.rub.), 199 cases of lifelong dis-
ability (44.6 m.rub.) and 276 cases of CC deaths annually. Total cost offsets could
amount to 811.6 m.rub. (664.8 m.rub. treatment cost only) representing 2.5x annual
cost of vaccinating one cohort of 12 year-old girls (328.9 m.rub.) (2.0x vs. treatment
cost only). The benefit-to-cost ratio (cost offset/vaccination cost) ranged from 1.8 to
3.1 over the sensitivity analyses. CONCLUSIONS: Implementation of HPV vaccina-
tion in the MR could significantly decrease cervical HPV-infection disease-related
burden. The cost of vaccination, at steady state, could be fully compensated by the
cost offset.
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OBJECTIVES:To investigate the extent to which using the most efficacious first-line
therapy to manage advanced non-small cell lung cancer (NSCLC) based on patients’
EGFR mutation status has clinical, economic, and quality of life (QoL) benefits from
diagnosis to death. METHODS: A deterministic cost-consequence model was de-
veloped to investigate alternative diagnostic and treatment strategies across mul-
tiple treatment lines in advanced NSCLC. Cost (drug and other treatment-related),
resource use, clinical, and QoL data were included. Cost and resource use data were
derived from the Dutch National Formulary, market research studies and expert
opinion. Clinical and QoL data – including progression-free survival (PFS) – were
derived from published studies and expert opinion. RESULTS:Different testing and
treatment strategies were modelled in a hypothetical population of 1,000,000 indi-
viduals. 498 patients presented with stage III/IV NSCLC. In the base-case (no EGFR
mutation testing) all patients received first-line doublet chemotherapy followed by
second-line docetaxel (50%) or best supportive care (50%). Total median PFS in the
population was 246.00 years (5.93 months per patient). Total healthcare costs, in-
cluding adverse event (AE) management, were €11,801,371 (€23,698 per patient).
EGFR mutation testing all patients identified 60 patients as EGFR mutation-posi-
tive. First-line treatments were assigned based on mutation status (EGFR muta-
tion-positive patients received gefitinib followed by second-line docetaxel, all oth-
ers were treated as in the base-case strategy). Compared with the base-case
strategy there was an 11.8% increase in total PFS (0.70 months per patient). Second-
line PFS increased 12.0%. Additionally, fewer AEs (anaemia, diarrhoea, dyspnoea,
febrile neutropenia, neurotoxicity and vomiting) and improved QoL were seen.
Excluding testing costs, total healthcare costs increased 17.4%. CONCLUSIONS:
Strategies where patients were appropriately treated based on EGFR mutation sta-
tus increased clinical and QoL benefits at relatively low incremental cost, com-
pared to strategies where patients were not tested or were treated sub-optimally.
Benefits extended beyond first-line treatment.
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OBJECTIVES: Two human papillomavirus (HPV) vaccines are available worldwide:
a bivalent vaccine (BV) targeting oncogenic high-risk HPV-16/18 and a quadrivalent
vaccine (QV) targeting both high-risk HPV-16/18 and low-risk HPV-6/11. Based on
data in their respective trials, BV is likely to have higher efficacy against non-
vaccine oncogenic HPV-types (cross protection). QV has an effect against genital
warts (GW). The potential effect of both vaccines in Thailand on cervical intraepi-
thelial neoplasia grade 1-3 (CIN1-3), GW, cervical cancer (CC) and related treatment
costs was investigated. METHODS: A static model estimated the above outcomes
over a one-year period at steady state versus the current situation. Costs were
assessed from a health care payer’s perspective. Epidemiological and cost data
were obtained from published sources; efficacy figures were based on the latest
clinical trial results from each vaccine and region-specific HPV distribution among
lesions (local data was used where possible). Sensitivity analyses were conducted
on all input data, such as with scenarios where the incidence and costs of treating
GW were varied. RESULTS: BV was projected to avert 9394 cases of CC annually. BV
potentially would result in an additional reduction of 5470 CIN1, 5177 CIN2/3 and
1113 CC cases annually compared with QV, while QV potentially would prevent an
additional 125,957 GW cases annually. The additional cost saved with BV was es-
timated at THB 356 million annually compared with QV. Sensitivity analyses report
additional cost-savings for the BV compared with QV under all scenarios.
CONCLUSIONS: The level of cross protection of BV potentially would allow for an
additional reduction in CC and HPV-related morbidity compared to QV; under our
model, this resulted in cost averted that offset the economic benefit QV will have in
preventing GW in Thailand.
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OBJECTIVES: Sunitinib is an oral multitargeted tyrosine kinase inhibitor approved
in Europe in 2010 for use in well-differentiated pancreatic neuroendocrine tumors
(pNET) that have spread or cannot be removed with surgery. This study evaluated
the cost-effectiveness of sunitinib  best supportive/palliative care (BSC) com-
pared to placebo  BSC in Portuguese patients. METHODS: A Markov model was
adapted to predict life-years (LY) and associated costs (€) of pNET patients’ treat-
ment over lifetime in Portugal. The model tracks transitions of patients between
three health states: progression free, post-progression and death. Transition prob-
abilities between health states and adverse events probabilities were based on
published results from the phase III pNET trial of sunitinib. BSC overall survival (OS)
probabilities were adjusted for crossover with a rank preserving structural failure
time (RPSFT) statistical analysis. Resource use was elicited through a panel of five
Portuguese experts with extensive clinical experience. Subsequent treatments are
not included given the lack of efficacy evidence. Adverse events treatment costs
and unit costs were extracted from Portuguese literature and official sources. A
National Health Service perspective was adopted and both costs and effectiveness
were discounted at 5%. RESULTS: Average cost per patient for sunitinib BSC and
placebo  BSC treatment were 54,215€ and 10,239€ respectively, while the average
effectiveness gained with sunitinib was 1.83LY. This resulted in an incremental
cost-effectiveness ratio (ICER) of 24,035€/LY. While the application of the RPSFT
method may have some limitations and therefore provide uncertainty regarding
the true OS benefit, the intent-to-treat classic analysis that does not correct for the
confounding effect of crossover generated an ICER of 34,387€/LY. CONCLUSIONS:
Compared with BSC, sunitinib treatment in patients with advanced or metastatic
unresectable pNET improve effectiveness in terms of life-years gained and is cost-
effective by the commonly used threshold in Portugal for assessment of new health
technologies.
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OBJECTIVES: To assess, from a UK NHS perspective, the cost-effectiveness of the
addition of rituximab (R) to selected chemotherapies: CVP (cyclophosphamide, vin-
cristine and prednisolone); CHOP (cyclophosphamide, doxorubicin, vincristine and
prednisolone) and MCP (mitoxantrone, chlorambucil and prednisolone) in the first-
line treatment of follicular lymphoma. METHODS: A patient level simulation
model was developed with four mutually exclusive and exhaustive health states:
progression free survival on first line treatment (the starting state); progression
free survival on second line treatment (PFS2); progression; and death (an absorbing
state). First-line treatment consisted of chemotherapy or R-chemotherapy. Pa-
tients relapsing before death move into PFS2 and are assumed to receive second-
line treatment dependent on initial treatment and time of relapse. After progres-
sion, patients enter the progression state where they reside until death. The model
horizon was 25 years with costs and benefits discounted at 3.5%. Separate analyses
were undertaken assuming rituximab maintenance for patients who responded to
R-chemotherapy in first-line induction. Evidence from phase III trial were used
when possible, however due to data limitations, assumptions were necessary
which increases the uncertainty in the results. RESULTS: The estimated Incremen-
tal Cost-Effectiveness Ratios (ICERs) for the addition of rituximab to CVP, CHOP and
MCP were £7,720, £10,834 and £9,316 per QALY gained respectively assuming no
first-line rituximab maintenance. The ICERs increased to £14,959, £21,687 and
£20,493 per QALY gained respectively when maintenance treatment was assumed.
The ICER was sensitive to assumptions regarding the choice of parametric distri-
bution to model the effectiveness of first-line treatment, the maximum time a
patient can remain progression-free and potential resistance to rituximab, with the
most favourable (unfavourable) ICER being approximately £4,000 (£61,000) per
QALY gained. CONCLUSIONS: The addition of rituximab to CVP, CHOP and MCP is
expected to fall below a cost per QALY gained of £25,000 regardless of the assump-
tion on maintenance.
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OBJECTIVES: The analysis of the sub-group of patients who received one prior
VEGF-TKI-based therapy in the RECORD-1 clinical trial reported a median progres-
sion-free survival of 5.42 months and 1.87 months for the everolimus and BSC-
alone arms, respectively. A Markov model was developed to assess the cost-effec-
tiveness of treating mRCC patients whose disease had failed on one prior VEGF-TKI
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therapy with everolimus versus BSC alone from the Canadian societal perspective.
METHODS: A Markov model simulated 2 hypothetical patient cohorts (everolimus
versus BSC alone) from the time of initial treatment throughout the 6-year time
horizon. The cost-effectiveness of everolimus was calculated in terms of cost per
life-years gained (LYG) as well as cost per quality-adjusted life year (QALY) gained.
Health state transition probabilities were derived directly from the RECORD-1 sub-
group analysis; costs and health state utility values were obtained from literature.
The analysis was performed from a societal perspective; as such, direct medical
costs and indirect costs associated with productivity loss due to morbidity or future
income loss attributed to early mortality were included. A sensitivity analysis from
the payer’s perspective was additionally performed. Outcomes and costs were dis-
counted at a 5% annual rate. RESULTS: Treatment with everolimus produced an
estimated gain over BSC alone of 0.643 LYG (0.455 QALYs) at an incremental cost of
$22,074. The deterministic analysis resulted in incremental cost-effectiveness ra-
tios (ICERs) of $34,326/LYG and $48,507/QALY. The payer’s perspective sensitivity
analysis resulted in ICERs of $48,670/LYG and $68,777/QALY. According to the prob-
abilistic sensitivity analysis, given a threshold of $100,000/QALY, the probability
that everolimus was cost-effective, from a societal perspective, was 100%.
CONCLUSIONS: Results of this analysis suggest that, from a Canadian societal
perspective, everolimus is a cost-effective alternative to BSC alone when treating
mRCC patients whose disease fails on one prior VEGF-TKI treatment.
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OBJECTIVES: Colorectal cancer (CRC) is the third most frequent worldwide and
about 28,110 new cases were expect for Brazil in 2010. Two biologic agents are
approved for treatment of mCRC in Brazil: cetuximab, exclusively for K-RAS wild-
type patients and bevacizumab, for both K-RAS types. We aimed to compare costs
and outcomes of bevacizumab versus cetuximab in first-line treatment of mCRC,
both in combination with FOLFIRI from a private payer perspective in Brazil.
METHODS: In the absence of head-to-head trials comparing BevFOLFIRI and
CetFOLFIRI, an adjusted indirect comparison was conducted using Bucher-
method. Hazard ratios (HRs) from 3 studies: BICC-C(part II) comparing BevFOLFIRI
vs BevIFL; AVF2107g comparing BevIFL vs IFL; and CRYSTAL comparing
CetFOLFIR versus FOLFIRI; were utilized. An illness-death Markov model was
enhanced. Risks for progression and mortality were derived from Weibull regres-
sion model (assuming deaths conditional upon prior progression). Natural mortal-
ity rates were applied according to IBGE life table. Only direct costs were considered
for patients with 1,78m2 and 70Kg. Ex-factory prices were obtained from official
public sources. Time-horizon was two years according to natural history of the
disease. Utilities were derived from international sources; discounting was 5% for
costs and outcomes, according to local guidelines. A probabilistic sensitivity anal-
ysis (PSA) was conducted in order to evaluate the robustness of results. Non-sta-
tistically significant HR 95%-CIs were exploited in PSA. RESULTS: Results of the
analysis suggest BevFOLFIRI combination is less costly compared to CetFOLFIRI
($Brz216,838.38 vs. $Brz276,770.15) and a trend towards improved effectiveness
with BevFOLFIRI (OS 20.1 vs. 16.60 months; QALYs 1.1 vs. 0.9) in first-line treat-
ment of mCRC. PSA portends that BevFOLFIRI is dominant over CetFOLFIRI
(93,44% of iterations BevFOLFIRI prolonged OS, being less costly). CONCLUSIONS:
Based on current available data, analysis suggest BevFOLFIRI presents lower costs
and better efficacy than CetFOLFIRI for treatment of first-line mCRC from a pri-
vate payer perspective in Brazil.
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OBJECTIVES: To determine the cost-effectiveness of erlotinib compared with do-
cetaxel every 3 weeks (D3W) or weekly (DW) or pemetrexed in second line treat-
ment for patients with advanced or metastatic NSCLC, from the Brazilian Private
Healthcare System perspective. METHODS: The analysis is based on a three stage
Markov model to estimate costs and consequences of treatments over 2 years.
Epidemiological and efficacy data were derived from a systematic literature search.
Indirect network meta-analysis assessed the relative efficacy of the compared
treatments. The survival curves were modeled by fitting a Weibull distribution.
Only direct medical costs were considered: Drug costs, daily hospital admission
rates, procedures and laboratory test unit cost were obtain from Brazilian official
databases of private healthcare system fees. Costs and benefits were discounted at
5% yearly and reported in 2010 Brazilian currency (BRL). Outcomes were expressed
as progression-free survival (PFS; months), overall survival (OS; months) and qual-
ity adjusted life years (QALY). Probabilistic sensitivity analysis (PSA) was conducted
to assess model robustness.RESULTS:Through the systematic literature review we
identified a network meta-analysis performed by Hawkins et al comparing BR21,
JMEI, TAX 317, ISEL, INTEREST and SIGN trials that formed the body of clinical data
for the analysis. The analysis showed higher clinical benefits and lower average
costs for erlotinib (9.73 OS; 4.24 PFS; 0.25 QALY; R$40,471) than D3W (8.49 OS; 3.21
PFS; 0.21 QALY; R$47,180) or DW (8.49 OS; 3.21 PFS; 0.21 QALY; R$56,549) or pem-
etrexed (8.49 OS; 3.31 PFS; 0.21 QALY; R$60,151), showing the dominance of erlo-
tinib related to compared treatments. PSA demonstrated that in 86%, 98% and 97%
of the simulations erlotinib was dominant compared to D3W, DW and pemetrexed.
CONCLUSIONS: This analysis portends that Erlotinib could be considered as a
dominant treatment strategy in 2nd line mNSCLC compared to docetaxel or pem-
etrexed under the Brazilian Private Healthcare System perspective.
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OBJECTIVES: The optimal intensity of conditioning prior to allogeneic hematopoi-
etic stem cell transplants (HSCT) remains uncertain. We present the result of the
prospective socio-economic evaluation associated with a randomized study com-
paring two levels of intensity reduction.METHODS:We compare reduced intensity
conditioning regimen (RIC Fludarabine, oral myleran and anti-thymocyte-globu-
lin) and non myeloablative conditioning regimen (NMAC Fludarabine and total
body irradiation). Direct medical transplant costs were estimated by micro-costing
on the basis of patients’ CRF until 18 months after transplant. Costs of treatment of
progression were estimated within five years after transplant. Cost-effectiveness
analysis was performed using overall survival (OS) and disease free survival (DFS)
as endpoint. Health-related quality of life (HRQL) was measured prospectively by
the EORTC QLQ-C30 questionnaire administered seven days before transplant and
on days 30 80 180 and 360. Linear mixed model analysis was performed to
test whether there were differences in HRQL outcomes within and between the two
groups over time. GVHD occurrence was included in the model. RESULTS:A total of
139 patients with hematological malignancies were treated (RIC: N69; NMAC:
N70). Survival and DFS at one and five years were identical after RIC and NMAC.
The mean total cost per patient was not different between groups (83,656€ for RIC
vs. 72,592€ for NMAC, NS). This is related to decreased post graft costs for NMAC
(-22,815€, p0.002) being offset by increased costs of disease progression (11,750€,
p0.008). Using DFS as endpoint, the RIC is cost-effective: incremental cost-effec-
tiveness ratio978.64 [95%IC313.23-2447.91]. Using OS no differences were found
between the two groups. RIC had a stronger negative impact on patients’ HRQL
independently of GVHD. CONCLUSIONS: The results confirmed the relapse/toxic-
ity arbitrage associated with the choice of the allo-HSCT conditioning regimen.
Moreover, the importance of the choice of endpoints and follow-up times in the
economic evaluation of cancer treatment is highlighted.
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OBJECTIVES: Maintenance treatment with Rituximab of follicular lymphoma (FL)
patients responding to first-line induction therapy with R-CHOP, R-CVP or R-FCM,
increases progression-free survival (hazard ratio 0.55; 95% CI 0.44 to 0.68, P0.0001)
compared with observation. We performed a cost-effectiveness analysis of main-
tenance therapy in first line of the FL with rituximab, compared with the option of
wait and watch strategy. METHODS: We developed a Markov model of the FL,
with four health states (progression free survival in first or second line, progression
and death). The transition probabilities between states were obtained from clinical
trials PRIMA and EORTC 20981. Health state utilities were obtained from literature.
The use of health resources, from the perspective of the National Health System
was estimated by a panel of Spanish onco-hematologist experts. Unitary costs (€ in
2010) were obtained from Spanish sources. Deterministic and probabilistic analy-
ses were performed. RESULTS: In the deterministic base case analysis, for a time
horizon of 30 years, the incremental cost per life year gained (LYG) and quality-
adjusted life-years (QALYs) gained, was €5663 and €6253 respectively. The sensi-
tivity analyses confirmed the stability of the base case for time horizons of 10 and
20 years and various statistical distributions (Weibull, exponential, log-logistic,
log-normal, Gompertz, and gamma) ranging between €4222 and €8766.
CONCLUSIONS: Compared with observation, rituximab maintenance treatment of
the FL that responds to inmunochemotherapy induction in first line, is a cost-
effective strategy.
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OBJECTIVES: Combinations of chemotherapy and monoclonal antibodies (MAbs)
against the vascular endothelial growth factor (bevacizumab) and the epidermal
growth factor receptor (cetuximab) have been shown to improve the clinical out-
come of patients with mCRC. Little is known about the economic implications of
their use. The aim of this analysis was to evaluate the cost, clinical- and cost-
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